First Evidence for a Dose-Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study
- PMID: 31601696
- DOI: 10.2967/jnumed.119.232751
First Evidence for a Dose-Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study
Abstract
166Ho-microspheres have recently been approved for clinical use for hepatic radioembolization in the European Union. The aim of this study was to investigate the absorbed dose-response relationship and its association with overall survival for 166Ho radioembolization in patients with liver metastases. Methods: Patients treated in the HEPAR I and II studies who underwent an 18F-FDG PET/CT scan at baseline, a posttreatment 166Ho SPECT/CT scan, and another 18F-FDG PET/CT scan at the 3-mo follow-up were included for analysis. The posttreatment 166Ho-microsphere activity distributions were estimated with quantitative SPECT/CT reconstructions using a quantitative Monte Carlo-based method. The response of each tumor was based on the change in total lesion glycolysis (TLG) between baseline and follow-up and was placed into 1 of 4 categories, according to the PERCIST criteria, ranging from complete response to progressive disease. Patient-level response was grouped according to the average change in TLG per patient. The absorbed dose-response relationship was assessed using a linear mixed model to account for correlation of tumors within patients. Median overall survival was compared between patients with and without a metabolic liver response, using a log-rank test. Results: Thirty-six patients with a total of 98 tumors were included. The relation between tumor-absorbed dose and both tumor-level and patient-level response was explored. At a tumor level, a significant difference in geometric mean absorbed dose was found between complete response (232 Gy; 95% confidence interval [CI], 178-303 Gy; n = 32) and stable disease (147 Gy; 95% CI, 113-191 Gy; n = 28) (P = 0.01) and between complete response and progressive disease (117 Gy; 95% CI, 87-159 Gy; n = 21) (P = 0.0008). This constitutes a robust absorbed dose-response relationship. At a patient level, a significant difference was found between patients with complete or partial response (210 Gy; 95% CI, 161-274 Gy; n = 13) and patients with progressive disease (116 Gy; 95% CI, 81-165 Gy; n = 9) (P = 0.01). Patients were subsequently grouped according to their average change in TLG. Patients with an objective response (complete or partial) exhibited a significantly higher overall survival than nonresponding patients (stable or progressive disease) (median, 19 mo vs. 7.5 mo; log-rank, P = 0.01). Conclusion: These results confirm a significant absorbed dose-response relationship in 166Ho radioembolization. Treatment response is associated with a higher overall survival.
Keywords: dose personalization; dose–response; dosimetry; holmium; radioembolization.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Dose-Effect Relationships of 166Ho Radioembolization in Colorectal Cancer.J Nucl Med. 2021 Feb;62(2):272-279. doi: 10.2967/jnumed.120.243832. Epub 2020 Jun 26. J Nucl Med. 2021. PMID: 32591491
-
(⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24819055 Clinical Trial.
-
Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.J Nucl Med. 2016 Jul;57(7):1014-9. doi: 10.2967/jnumed.115.166942. Epub 2016 Feb 23. J Nucl Med. 2016. PMID: 26912436 Clinical Trial.
-
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.Semin Nucl Med. 2019 May;49(3):237-243. doi: 10.1053/j.semnuclmed.2019.01.008. Epub 2019 Feb 1. Semin Nucl Med. 2019. PMID: 30954190 Review.
-
Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21. Cardiovasc Intervent Radiol. 2022. PMID: 35729423 Free PMC article. Review.
Cited by
-
Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?World J Gastroenterol. 2024 May 14;30(18):2379-2386. doi: 10.3748/wjg.v30.i18.2379. World J Gastroenterol. 2024. PMID: 38764771 Free PMC article. Review.
-
Gamma camera imaging characteristics of 166Ho and 99mTc used in Selective Internal Radiation Therapy.EJNMMI Phys. 2024 Apr 6;11(1):35. doi: 10.1186/s40658-024-00633-3. EJNMMI Phys. 2024. PMID: 38581559 Free PMC article.
-
Impact of scatter correction on personalized dosimetry in selective internal radiotherapy using 166Ho-PLLA: a single-center study including Monte-Carlo simulation, phantom and patient imaging.EJNMMI Phys. 2024 Apr 2;11(1):33. doi: 10.1186/s40658-024-00639-x. EJNMMI Phys. 2024. PMID: 38564100 Free PMC article.
-
Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2114-2123. doi: 10.1007/s00259-024-06645-6. Epub 2024 Feb 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38369678 Free PMC article.
-
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts.Cancers (Basel). 2024 Jan 4;16(1):235. doi: 10.3390/cancers16010235. Cancers (Basel). 2024. PMID: 38201662 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources